Form 13-F position report

REVELATION BIOSCIENCES INC

Reported by SABBY MANAGEMENT LLC

REVB CUSIP 76135L804 Manager CIK 0001535610

Reported 126,915 shares, down 83,667 (39.7%) from the prior quarter.

Reported value -52.2%; share count -39.7% vs. the prior quarter.

Reduced
% of reported 13F value 1.15% This manager · Q3 2026
Shares 126,915 Quarter-end amount reported
Reported value $103,690 Fair value at quarter end
Consecutive quarters held 6 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-03-31 234560
2023-06-30 332039
2023-09-30 277989
2023-12-31 201899
2024-03-31 0
2024-09-30 35968
2024-12-31 0
2025-06-30 49342
2025-09-30 0
2025-09-30 294012
2025-12-31 484440
2026-03-31 0
2026-03-31 119318
2026-06-30 216899
2026-09-30 103690

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for REVELATION BIOSCIENCES INC held by SABBY MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 126,915 -83,667 (-39.7%) 1.15% $103,690 2026-11-13
Q2 2026 Added 210,582 +111,150 (111.8%) 0.2% $216,899 2026-08-14
Q1 2026 New 99,432 +99,432 (0.0%) 0.26% $119,318 2026-05-15
Q1 2026 Reduced 0 -605,702 (-100.0%) 0 $0 2026-05-15
Q4 2025 Added 605,702 +398,651 (192.5%) 0.7% $484,440 2026-02-17
Q3 2025 New 207,051 +207,051 (0.0%) 0.34% $294,012 2025-11-14
Q3 2025 Reduced 0 -65,789 (-100.0%) 0 $0 2025-11-14
Q2 2025 New 65,789 +65,789 (0.0%) 0.09% $49,342 2025-08-14
Q4 2024 Reduced 0 -42,226 (-100.0%) 0 $0 2025-02-14
Q3 2024 New 42,226 +42,226 (0.0%) 0.02% $35,968 2024-11-14
Q1 2024 Reduced 0 -403,233 (-100.0%) 0 $0 2024-05-15
Q4 2023 Unchanged 403,233 0 (0.0%) 0.2% $201,899 2024-02-14
Q3 2023 Added 403,233 +50,000 (14.2%) 0.2% $277,989 2023-11-14
Q2 2023 Added 353,233 +172,802 (95.8%) 0.27% $332,039 2023-08-14
Q1 2023 New 180,431 +180,431 (0.0%) 0.2% $234,560 2023-05-15

Who else reported the position

14 managers reported REVELATION BIOSCIENCES INC for Q3 2026.

Managers reporting REVELATION BIOSCIENCES INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
SABBY MANAGEMENT LLC This report Reduced 126,915 -83,667 1.15% $103,690 3 qtrs
CITADEL ADVISORS LLC Added 99,431 +60,852 < 0.01% $81,235 2 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP New 18,928 +18,928 < 0.01% $15,464 1 qtr
GEODE CAPITAL MANAGEMENT LLC Unchanged 17,192 0 < 0.01% $14,045 3 qtrs
UBS Group AG New 13,282 +13,282 < 0.01% $10,852 3 qtrs
VANGUARD FIDUCIARY TRUST CO Unchanged 13,127 0 < 0.01% $10,725 3 qtrs
Tower Research Capital LLC TRC Reduced 3,888 -2,640 < 0.01% $3,176 3 qtrs
ROYAL BANK OF CANADA Added 855 +108 < 0.01% $1,000 3 qtrs
BNP Paribas Asset Management Holding S A Unchanged 9 0 < 0.01% $7 3 qtrs
Citigroup Inc New 6 +6 < 0.01% $5 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
126,915
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.